ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Monday, October 27, 2025

10:30AM-12:30PM: Abstract Number: 1417

Common Causes of Hospitalization in Spondyloarthritis Patients: A Nationwide Analysis

(1405–1433) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1023

Comparative Analysis of Oral Health and Dental Care in Patients With Immune-Mediated and Non-Immune-Mediated Rheumatic Diseases

(1007–1037) Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 1224

Comparative Effectiveness of Duloxetine versus Pregabalin in Fibromyalgia: A Large-Scale, Real-World Study Across 300,000 Patients

(1221–1247) Pain in Rheumatic Disease Including Fibromyalgia Poster

10:30AM-12:30PM: Abstract Number: 1161

Comparative efficacy, safety and tolerability of antifibrotic therapies across systemic autoimmune diseases

(1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

10:30AM-12:30PM: Abstract Number: 1359

Comparative Safety Outcomes of Tofacitinib Versus Upadacitinib in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study

(1347–1375) Rheumatoid Arthritis – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1494

Comparing Childhood-Onset Versus Adult-Onset Systemic Lupus Erythematosus Young Adults’ Lived Employment Experiences

(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1495

Comparing the 0-10 Physician Global Assessment Scale to Categorical Disease Activity States among Pediatric Patients with SLE

(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1089

Comparing the immunosuppressant burden in immune checkpoint inhibitor mediated inflammatory arthritis versus polymyalgia rheumatica: results from a prospective multicenter registry

(1088–1122) Immunological Complications of Medical Therapy Poster

10:30AM-12:30PM: Abstract Number: 1638

Comparison and Assessment of the All of Us Dataset for Epidemiologic Studies of Systemic Lupus Erythematosus (SLE) Among African American Women

(1633–1649) ARP Posters II: ARP Epidemiology & Public Health

10:30AM-12:30PM: Abstract Number: 1593

Comparison of rituximab induction and maintenance regimens in ANCA-associated vasculitis: PK/PD modelling approach in real-world patients

(1592–1611) Vasculitis – ANCA-Associated Poster II

10:30AM-12:30PM: Abstract Number: 1440

Comparison of standard and tapered dose of biologic treatments in patients with axial spondyloarthritis

(1434–1466) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1473

Comparison of Three Different Double-Stranded DNA Antibody Assays in the Diagnosis of Systemic Lupus Erythematosus

(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 0932

Compartment-specific NK-cell phenotypes reveal distinct maturation and activation states in inflammatory arthritis

(0916–0933) Innate Immunity Poster

10:30AM-12:30PM: Abstract Number: 1572

Compromised intracellular oxygen availability and severe mitochondrial dysfunction in the skeletal muscle of patients with systemic sclerosis

(1553–1591) Systemic Sclerosis & Related Disorders – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1639

Concordance of Self-Reported Physical Functioning and Physical Performance in SLE: A Cross-Cohort Analysis

(1633–1649) ARP Posters II: ARP Epidemiology & Public Health

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].